Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVID-19 prophylaxis in immunosuppressed kidney transplant recipients using AZD7442
2021-006960-26Phase 4Terminated
- Sponsor
- Oslo University Hospital
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, single-arm trial of tixagevimab + cilgavimab in coronavirus disease 2019 (COVID-19), sponsored by Oslo University Hospital. Primary endpoint: AZD7442 serum concentrations. Started Aug 2022; status: terminated.
02
Drugs
tixagevimab + cilgavimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-006960-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006960-26.